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The magnitude and temporal changes of
response in the placebo arm of surgical
randomized controlled trials: a systematic
review and meta-analysis
Karolina A. Wartolowska1,2*, Benjamin G. Feakins3, Gary S. Collins2,4, Jonathan Cook2, Andrew Judge2,5,
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Abstract
Background: Understanding changes in the placebo arm is essential for correct design and interpretation of
randomized controlled trials (RCTs). It is assumed that placebo response, defined as the total improvement in the
placebo arm of surgical trials, is large; however, its precise magnitude and properties remain to be characterized. To
the best of our knowledge, the temporal changes in the placebo arm have not been investigated. The aim of this paper
was to determine, in surgical RCTs, the magnitude of placebo response and how it is affected by duration of follow-up.
Methods: The databases of MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov
were searched from their inception to 20 October 2015 for studies comparing the efficacy of a surgical intervention with
placebo. Inclusion was not limited to any particular condition, intervention, outcome or patient population. The
magnitude of placebo response was estimated using standardized mean differences (SMDs). Study estimates were
pooled using random effects meta-analysis. Potential sources of heterogeneity were evaluated using stratification and
meta-regression.
Results: Database searches returned 88 studies, but for 41 studies SMDs could not be calculated, leaving 47 trials
(involving 1744 participants) eligible for inclusion. There were no temporal changes in placebo response within the
analysed trials. Meta-regression analysis showed that duration of follow-up did not have a significant effect on the
magnitude of the placebo response and that the strongest predictor of placebo response was subjectivity of the
outcome. The pooled effect in the placebo arm of studies with subjective outcomes was large (0.64, 95% CI 0.5 to 0.8)
and remained significantly different from zero regardless of the duration of follow-up, whereas for objective outcomes,
the effect was small (0.11, 95% CI 0.04 to 0.26) or non-significant across all time points.
Conclusions: This is the first study to investigate the temporal changes of placebo response in surgical trials and the first
to investigate the sources of heterogeneity of placebo response. Placebo response in surgical trials was large for
subjective outcomes, persisting as a time-invariant effect throughout blinded follow-up. Therefore, placebo response
cannot be minimized in these types of outcomes through their appraisal at alternative time points. The analyses suggest
that objective outcomes may be preferable as trial end-points. Where subjective outcomes are of primary interest, a
placebo arm is necessary to control for placebo response.
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Background
There is an increasing interest in surgical randomized con-
trolled trials (RCTs) with a placebo arm [1]. However, the
magnitude and duration of the placebo response following
surgical procedures, i.e. the effect not related to the main
surgical maneuvers, has not been characterized. Some au-
thors have suggested that the placebo response in surgery
is large [2] and, like pharmacological treatment, has a
time-effect curve, with a peak and a carry-over effect [3].
Studies of non-surgical placebos have demonstrated
that the outcome type affects the magnitude of placebo
response, with subjective outcomes resulting in a larger
placebo response than objective ones [4]. Moreover, in
studies with subjective outcomes, placebo response was
larger in pain outcomes than in function outcomes [5].
Other trial characteristics that have been suggested to
affect placebo response include the number of subjects
[4, 6], the frequency of face-to-face visits [7] or placebo
administration [6], the randomization ratio [7], subject
baseline pain intensity [7], the study design (parallel ver-
sus cross-over) and the location of the study (Europe
versus North America) [8].
Two recent reviews of surgical RCTs have observed a
large effect in the placebo arm which explained about
80% of the variance of the effect within the surgical arm
[9] and accounted for 65% of the overall improvement
[10]. However, the dependence of placebo response on
the time of the follow-up assessment has not been inves-
tigated. Our previous review [1] focussed on comparing
the active and placebo arms of surgical RCTs in terms of
“harms” (assessed as serious adverse events) and benefits
(estimated as the effect size in the surgical arm in com-
parison to the placebo arm) [1]. Within the included stud-
ies, the benefits of the surgical intervention relative to the
placebo were generally small, and we did not specifically
investigate improvement within the placebo arm.
The terms “placebo effect” and “placebo response” are
often used interchangeably [6, 7]. In this paper, the term
“placebo effect” was used to refer to the “true placebo
effect”, i.e. the changes in response associated with the
meaning of treatment [11], conditioning and expectations
[12]. The term “placebo response” was used to describe the
improvement, i.e. the difference between the baseline and
follow-up measures, in the placebo arm (Fig. 1). Differences
between placebo effect and placebo response have been
discussed in depth previously by Ernst and Resch [12]. The
magnitude of placebo response represents a compound
effect, only a portion of which may be attributable to the
true placebo effect. The remainder of the response within
the placebo arm may reflect non-specific effects. These
include statistical phenomena (such as regression to mean),
biological aspects of disease progression or natural history
of the disease and psychological effects of being observed
by and receiving attention from clinical staff.
It is assumed that surgery has a large effect on study
outcomes and therefore the difference between the sur-
gical and placebo arm is large [13]. However, reviews of
published placebo-controlled surgical trials have dem-
onstrated that the effect size in both arms can be sub-
stantial, whilst the difference in effect between the arms
is often small [1, 9]. This suggests that some surgical
procedures may be truly ineffective, with most of the
observed improvement attributable to the effect of
non-specific factors. Alternatively, some trials may fail
to demonstrate the superiority of treatment over pla-
cebo, not because of the ineffectiveness of the proced-
ure, but because the observed effect of surgery versus
placebo is small [1, 7]. In the latter scenario, a larger
sample size would be required to detect a difference
between the groups.
Understanding the characteristics of response in the
placebo arm is important for both the design and in-
terpretation of placebo-controlled RCTs. If improve-
ment in the placebo arm changes over time, the
choice of assessment timing may affect the results of
the trial.
The aim of this study was to estimate the magnitude
of the placebo response in surgical RCTs and examine
the factors on which it depends: mainly whether the
effect changes over time and for how long it persists.
Methods
Search strategy
The criteria used to identify placebo-controlled surgical
RCTs have been described previously [1]. In brief, the
databases of Medical Literature Analysis and Retrieval
Fig. 1 Elements contributing to improvement in the surgical and
placebo arms
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System Online (MEDLINE), Excerpta Medica data-
BASE (EMBASE) and the Cochrane Central Register of
Controlled Trials were searched for RCTs in which the
efficacy of surgery was compared to a surgical placebo.
(Details of the search terms can be found in Additional
file 1.) ClinicalTrials.gov, a database of registered RCTs,
was also queried to identify any recently completed stud-
ies with published results. The searches were performed
on 20 October 2015.
Five reviewers (KAW, IR, BJFD, JAS, BGF) screened the
initial set of abstracts identified from the database search.
The reviewers independently assessed the eligibility of
each study abstract and the full text, and the final list of
included studies was agreed upon by consensus.
Eligibility criteria
Studies were eligible for inclusion if they investigated the
efficacy of surgery through comparison to a placebo pro-
cedure, and if they reported a continuous primary out-
come measure for which the effect size could be
calculated. Trials were also included if they specified a
non-continuous primary outcome, i.e. a dichotomization
of a continuous measure, but provided the mean and
standard deviation (SD) for the measure on which the
primary outcome was based. For example, trials were
included in which the outcome was defined as a 50%
improvement in pain but the mean and SD or 95% con-
fidence intervals (CIs) for the pain scores were reported.
“Surgery” was defined as any interventional procedure
that changed the anatomy and required a skin incision
or the use of endoscopic techniques. Dental studies and
invasive procedures used to deliver a pharmacological
substance or stem cells, or that aimed to alleviate symp-
toms by modulation, stimulation or denervation were
excluded.
The term “placebo” was used to refer to a surgical pla-
cebo, a sham surgery or an imitation procedure intended
to mimic the active intervention, including the scenario
where a scope was inserted but no active procedure was
performed whilst patients were sedated or under general
anaesthesia and could not determine whether or not
they had received the surgical intervention. Trial inclu-
sion was not limited to any particular condition, inter-
vention, outcome or patient population.
Data extraction
The main characteristics of each trial were entered in
the standardized data extraction form, including the
publication year, country in which the trial was con-
ducted, blinding (who was blinded), randomization ra-
tio, key characteristics of the surgical and placebo
procedure (including concomitant standard treatment
such as levodopa in Parkinson’s trials or analgesics in pain
trials) as well as outcome details (including the type of
outcome and the primary assessment time point). Out-
comes were classified as “subjective”, i.e. patient-reported
and depending on the patients’ perception and cooper-
ation, “assessed”, i.e. subjective ratings judged by external
assessors or “objective”, i.e. measured using devices or
laboratory tests and independent of patients’ or observers’
perception, for example weight.
For each study time point of each trial, the following
data were recorded: the mean and SD of the outcome in
the placebo arm, the number of individuals in the pla-
cebo arm, the time point number (1st follow-up, 2nd
follow-up, etc.) and time since the placebo procedure
was conducted. For trials that only reported the out-
comes in figures, values were extracted from the figures.
Where the SD of the outcome was not reported at
follow-up, the SD of the baseline value was used, under
the assumption that there was no strong mean-variance
relationship.
Data were extracted for all primary outcomes. If there
was more than one primary outcome or the primary
outcome was not defined, the outcome used in the sam-
ple size calculation was chosen. Where neither of these
was reported, the first outcome mentioned in the ab-
stract was used. No attempts were made to contact the
authors of identified trials. Where necessary, the direc-
tion of effect was reversed, so that improvement was
consistently presented in the same direction, i.e. as a
reduction in SMD. In cross-over trials, the data from the
cross-over time point were used as the primary assess-
ment time point for the primary study outcome. If the
follow-up was longer than the blinding, the data from
the last blinded follow-up visit were used.
Data synthesis and analysis
Study effect size was quantified as standardized mean
differences (SMDs), which were calculated from the
baseline and follow-up values of the mean and SD of
the study outcomes using Cohen’s d method [14, 15] at
each follow-up time point. A pretest-posttest correl-
ation coefficient (r) of 0.5 was used to calculate the
standard error of the SMD, if not otherwise reported.
The value for r was estimated from 11 trials that re-
ported both the SD of the mean and the SD of differ-
ence between the means [14]. The median value of r in
these studies was 0.5, ranging from 0.2 to 0.6. The ef-
fects of potentially misspecifying the value of r were
evaluated in sensitivity analyses.
SMDs greater than 0.8 are usually considered to be
large, and SMDs between 0.5 and 0.8 are considered to
be moderate [15, 16]; however, there is no consensus on
the interpretation of the magnitude of effect sizes.
To estimate the magnitude of placebo response, a
meta-analysis was used to calculate the pooled effect in
the placebo arms across all the trials with continuous
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outcomes, subgrouped by outcome type, as in the meta-
analysis by Hróbjartsson and Gøtzsche [17]. The magni-
tude of the placebo response was calculated as the effect
size for the primary outcome at the primary assessment
time point.
The effect of follow-up time on placebo response was
evaluated by meta-regression. Time, in months, was en-
tered as a continuous variable. Only one follow-up visit
was used per trial, i.e. the primary assessment time
point. Other potential trial-level factors reported in the
literature as affecting the magnitude of placebo response
(or placebo effect) were also investigated, including type
of outcome (subjective versus objective and assessed
versus objective), study location (North America, i.e. the
USA or Canada, versus other countries, where multicen-
ter trials were classified as “other countries”), blinding
(whether assessor was reported as blinded or not; blinding
of patients was an inclusion criterion) and randomization
ratio (balanced, i.e. 1:1 versus unbalanced, i.e. with a larger
number of patients randomized to the surgical arm). Add-
itionally, we analysed whether the presence of a concomi-
tant standard treatment, either throughout follow-up or as
a rescue medication, had an effect on the magnitude of
response in the placebo arm.
To further investigate temporal changes over the course
of the observed follow-up, meta-analyses were performed
in which pooled SMD estimates were grouped by follow-
up time (in months ± 2 weeks).
Random-effects models were used in all statistical ana-
lyses to account for the potentially high levels of between-
study heterogeneity anticipated from pooling different
types of surgical trials, outcomes and patient populations.
For standard meta-analysis models, the DerSimonian and
Laird method was used to derive between-study hetero-
geneity estimates, whilst for meta-regression models, re-
stricted maximum likelihood was used. In all instances,
between-study heterogeneity was quantified as the I2
statistic [18]. In order to estimate the magnitude of pla-
cebo response in a future trial, we also calculated 95%
prediction intervals [19].
The risk of bias in the included studies was assessed
using the risk of bias tool criteria recommended by the
Cochrane guidelines [20, 21]. Funnel plots [22] and
Egger’s test [23] were used to determine the presence of
possible publication bias.
The statistical analysis was performed in Stata 12.1
SE [24] using the “metan” [25], “metareg” [26], “meta-
bias” [27] and “metafunnel” [28] packages.
Results
Study selection
The search identified 88 full-text papers reporting surgi-
cal RCTs with a placebo arm. Forty-one studies were
excluded because either they reported non-continuous
primary outcomes (n = 21/47, 45%) or they reported a
median value or a change score, from which the SMD
could not be calculated (n = 20/47, 43%). This left 47 tri-
als (involving 1744 participants) eligible for inclusion in
the analysis. See the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) flow
diagram [29] in Fig. 2, the PRISMA checklist in Additional
file 2 and the list of all identified placebo-controlled RCTs
in Additional file 3.
Study characteristics
The median number of patients randomized to the pla-
cebo arm was 26, inter-quartile range (IQR) 16–55. The
included trials investigated heterogeneous conditions
and procedures. The characteristics of the included tri-
als, such as investigated condition, type of surgery, coun-
try in which the trial was undertaken, type of blinding,
outcomes and randomization ratio are presented in
Additional file 4. Nearly two-thirds of the trials used a
subjective primary outcome (n = 31/47, 66%). In six trials
(13%), including three studies on Parkinson’s disease, the
outcome was rated by a blinded assessor, and in ten tri-
als (21%) the outcome was objective.
All but seven trials (15%) were double-blinded (blinded
patients and assessors). Two of the single-blinded (only
patients blinded) trials had an objective outcome (weight
loss or glycated hemoglobin levels), whilst the other five
used patient-reported outcomes (quality of life or severity
of symptoms).
The randomization ratio was balanced, i.e. 1:1, in 32
trials (68%) and unbalanced in favour of the active treat-
ment in 14 trials (2:1 in 11 trials and 3:1 in 3 trials). One
study also included an observational group and had a
randomization ratio of 1:1:1. This study was classified as
having balanced randomization because the observational
group was unblinded; therefore, the randomization of the
blinded patients was balanced between the surgery and
placebo groups.
A cross-over design was used in 3 studies, in 22 stud-
ies patients were given an option to cross over after the
unblinding, whilst 22 trials did not report whether pa-
tients were given the option to cross over.
In 40 trials, there was only one treatment visit, 3 of-
fered “retreatment” and 4 used devices for a prolonged
period of time.
Apart from the anaesthesia or analgesia necessary for
interventional procedures, most of the trials (n = 37/47,
79%) also offered all patients a standard pharmacological
treatment, rescue medication or other treatment such as
diet or exercise. Only ten trials (21%) did not report
using any additional treatment in the placebo arm.
The median primary assessment time point was
6 months, ranging from 1 day to 2 years. In half of the
trials, the primary outcome was assessed at the first
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follow-up time point (n = 25/47, 53%). The largest num-
ber of follow-up time points between the procedure and
the primary outcome assessment was nine. About two-
thirds of studies used a subjective primary outcome
(n = 30/47, 64%), in seven trials the outcome was rated
by a blinded assessor and in ten trials the outcome
was objective.
Placebo response across all trials
The pooled estimate for placebo response across all tri-
als was 0.50 (95% CI 0.38–0.62) with the 95% prediction
interval for a future trial (−0.22 to 1.21). Heterogeneity
was substantial (I2 = 79%). When stratified by outcome
type, the effect size was moderate for subjective out-
comes (0.64, 95% CI 0.51–0.77), but there was no signifi-
cant pooled effect for assessed (0.22, 95% CI −0.20 to
0.64) or objective outcomes (0.11, 95% CI −0.04 to 0.26)
(Fig. 3). For trials with assessed outcomes, the pooled
effect was affected by the trial on advanced Parkinson’s
disease [30], in which the main outcome assessment was
after 2 years, during which time patients deteriorated as
a result of disease progression. Within each outcome type,
trials were ordered by follow-up time, but there was no
clear effect of duration of follow-up on the magnitude of
the SMD (Fig. 3).
Analysis of sources of heterogeneity in all trials
Duration of follow-up did not have a significant effect
on placebo response in univariable meta-regression ana-
lyses (Fig. 4). The randomization ratio, the use of
concomitant standard treatment and the evaluation of
assessed outcomes also had no statistically significant ef-
fect on placebo response in univariable meta-regression
analyses. The only factors significantly associated with
the magnitude of response were the subjectivity of out-
come and trial location. When these two variables were
combined as predictors in a multivariable meta-regression
analysis, both remained significant (Fig. 5).
Fig. 2 PRISMA flow diagram
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Analysis of temporal changes in trials with similar
outcomes
Analyses were limited to trials with similar outcomes, in
order to make the trials more comparable and reduce
between-trial heterogeneity. The most common subjective
primary outcome was average pain intensity (n = 11/47,
23%). For these trials, the pooled effect size was moderate
to large, 0.77 (95% CI 0.59–0.96) (Fig. 6).
Fig. 3 Meta-analysis of all trials. Pooled SMD estimates across all trials assessed at the primary assessment time point, grouped by outcome type and
ordered by duration of follow-up (in months). AUASI American Urological Association Symptom Index, BMI body mass index, CC-FI Cleveland Clinic
Florida - Faecal Incontinence score, CPAP continuous positive airway pressure, ESS Epworth Sleepiness Scale, HbA1c glycated hemoglobin, IBFAT Infant
Breastfeeding Assessment Tool, IPSS International Prostate Symptom Score, LBOS Low Back Outcome Score, MDRS Mattis Dementia Rating Scale, NRS
numerical rating scale, QoL quality of life, RDQ Roland–Morris Disability Questionnaire, SF-36 Short Form Health Status Questionnaire, SF-MPQ McGill
Pain Questionnaire, UPDRS Unified Parkinson’s Disease Rating Scale, VAS visual analogue scale, WOMAC Western Ontario and McMaster Universities
Osteoarthritis Index, Y-BOCS Yale–Brown Obsessive Compulsive Scale
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When pain intensity effect sizes were grouped by time
to follow-up, the pooled effect sizes were large and com-
parable across time points, from 1.04 (95% CI 0.87–to
1.2) at 2 weeks to 0.80 (95% CI 0.62–to 0.98) at 6 months
and 0.90 (95% CI 0.55–to 1.25) at 12 months (Fig. 7).
In Fig. 7, different trials contributed to the pooled ef-
fect in each subgroup; therefore, analysis was performed
using only trials with the same outcomes and similar
follow-up timings. For most time points, only a relatively
small number of studies contributed data to the pooled
estimate. There were three trials [31–33] with pain as an
outcome and assessment at 2 weeks and 1 month (Fig. 8)
and another three trials [34–36] with pain as the
outcome and assessments at 3, 6 and 12 months (Fig. 9).
This analysis showed that the effect size was comparable
between follow-up time points.
The most common objective outcome was weight
loss, constituting the primary outcome in four trials
(n = 4/47, 9%). For these trials, there was a smaller es-
timated pooled effect with no clear statistical evidence
of a difference, SMD= 0.20 (95% CI −0.02 to 0.41; I2 = 0)
(Fig. 10). A significant pooled effect at the first two follow-
up time points was driven by the trial by Eid et al. [37].
The loss of this significance in subsequent visits could be
attributable to diminishing patient adherence to diet and
exercise regime with time (Fig. 11).
Fig. 4 Univariable meta-regression of the factors affecting the SMD at the primary assessment time point
Fig. 5 Multivariable meta-regression of the factors affecting the SMD at the primary assessment time point
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Risk of bias assessment
The risk of bias assessment of each trial is given in
Additional file 5. The risk of bias was generally low.
However, some aspects could not be assessed due to
limited reporting. For example, only 57% of the trials
clearly described sequence generation and allocation
concealment. The blinding procedure was described in
enough detail to rule out bias in 79% of trials (n = 37/47).
In all studies, patients were blinded and in 85% (n = 40/47)
assessors were also blinded. All trials reported the primary
outcomes, but only 57% (n = 27/47) used a single primary
outcome. Thirty-two percent of the studies (n = 15/47) did
not report results of the intention-to-treat analysis.
The funnel plot in Fig. 12 appeared symmetrical,
implying an absence of publication bias. This observa-
tion was corroborated by the results of Egger’s test,
which was unable to determine the presence of statis-
tically significant plot asymmetry (p = 1.00). Several
studies fell outside the 95% CIs of the funnel plot in
Fig. 12, with a large number of these having relatively
high precision in their effect size estimates. This may
have resulted from pooling of trials that were largely
heterogeneous. A similar distribution of study effect
sizes has been reported in a Cochrane review of pla-
cebo interventions [38].
Sensitivity analysis
The meta-analysis model of the primary analysis of all 47
trials was re-run using r values of 0.3 and 0.7. The pooled
effect across all trials was 0.50 (CI 0.38–0.62, I2 = 67%) for
r = 0.2 and 0.50 (CI 0.38–to 0.61, I2 = 83%) for r = 0.6. This
resulted in minimal differences in the pooled effects for
each type of outcome.
Discussion
Main findings
There were no temporal changes in placebo response
within the analysed trials, and the response remained
comparable between follow-up time points. Meta-
regression analysis showed that the duration of follow-
up had no effect on placebo response. The magnitude of
response depended primarily on the outcome type, i.e.
whether the outcome was subjective or objective. For tri-
als with subjective outcomes, the pooled effect size of
placebo response was large and it persisted for the dur-
ation of the blinded follow-up; i.e. the follow-up values
did not return to baseline. However, for trials with ob-
jective outcomes, the effect was small or not significant
across all time points.
Strengths and limitations
This study is a comprehensive search and analysis of
placebo-controlled surgical RCTs identified through a
systematic search. It is, to the best of our knowledge, the
first study to characterize temporal changes in response
in the placebo arm of surgical RCTs.
Data could not be included from 41 out of 88 identi-
fied trials, because the primary outcomes were binary,
reported as medians with IQRs or were not associated
Fig. 6 Meta-analysis of pain trials at the primary assessment time point. Pooled SMD estimates for 11 trials with pain intensity as the primary
outcome at the primary assessment time point, ordered by follow-up time (in months). SF-MPQ McGill Pain Questionnaire, NRS numerical rating
scale, VAS visual analogue scale, SF-36 Short Form Health Status Questionnaire, WOMAC Western Ontario and McMaster Universities
Osteoarthritis Index
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with any data that could be extracted from the text or
the figures. We did not include secondary outcomes.
Within studies eligible for inclusion, analyses were
limited to the use of aggregate data, as reported by
trial authors, rather than individual patient data. The
lack of precision of our analyses reflected the rela-
tively low number and small size of included studies
and therefore did not investigate the effect of patient-
level factors such as age, sex or expectations, which
have been suggested to affect the magnitude of pla-
cebo response.
This study did not assess the effect or success of blind-
ing, as these checks are unable to distinguish between
the ineffectiveness of blinding from patient “hunches”
regarding perceived treatment efficacy [39]. The effect of
re-treatment could also not be investigated, as most
reviewed studies used a “one-off” intervention [1], with
only three studies using repeated placebo procedures.
The number of follow-up time points, i.e. whether the
primary outcome was assessed at the first or at a subse-
quent visit, was not used in the meta-regression because
it was correlated with follow-up time.
Fig. 7 Meta-analysis of pain trials grouped by follow-up time. Pooled SMD estimates for 11 trials with pain intensity as the primary outcome at
multiple follow-up visits, grouped by follow-up time (in months). SF-MPQ McGill Pain Questionnaire, NRS numerical rating scale, VAS visual
analogue scale, SF-36 Short Form Health Status Questionnaire, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index
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We have performed a meta-analysis of placebo re-
sponse under the assumption that the placebo interven-
tion is inactive, and therefore comparable across trials.
Few trials evaluated similar conditions or interventions
or used comparable follow-up time points; for example,
the included 47 trials investigated 28 different condi-
tions. Thus, our ability to explain the potential sources
of heterogeneity through subgroup and meta-regression
analysis was limited, and much of the heterogeneity
remained unexplained. Some heterogeneity may have
Fig. 8 Meta-analysis of pain trials with comparable early follow-up times. Pooled SMD estimates for three trials with pain intensity as the primary outcome
and follow-up visits before 2 weeks and at 1 month, ordered by sample size within subgroup. NRS numerical rating scale, VAS visual analogue scale
Fig. 9 Meta-analysis of pain trials with comparable late follow-up visits. Pooled SMD estimates for three trials with pain intensity as the primary
outcome and follow-up visits at 3, 6 and 12 months, ordered by sample size within subgroup. NRS numerical rating scale, VAS visual analogue
scale, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index
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been related to factors we did not investigate. It has been
demonstrated by Vase and colleagues [7] that most of
the between-trial heterogeneity is caused by patient-level
characteristics (to which we had no access) rather than
trial-level factors.
Interpretation
It is likely that the placebo response is not just the true
placebo effect, which has been demonstrated to be
small [4, 38], but possibly also the result of concomi-
tant treatment, natural history of the disease and
Fig. 10 Meta-analysis of weight loss trials at the primary assessment time point. Pooled SMD estimates for four trials with weight loss as the
primary outcome, ordered by follow-up time (in months)
Fig. 11 Meta-analysis of weight loss trials grouped by follow-up time. Pooled SMD estimates for four trials with weight loss as the primary
outcome, grouped by follow-up time (in months)
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regression to the mean, which are discussed in more
detail in the following paragraphs.
We could not investigate the extent to which placebo
response is caused by the true placebo effect, because
only one reviewed trial included a non-interventional
group [40] that could be used to control for the natural
history of disease and other non-specific changes [4]. It
is plausible that the sustained large placebo response in
trials with subjective outcomes may be a result of the
physiological effects directly related to placebo [9].
From the extensive analysis by Hróbjartsson and
Gøtzsche [4, 17, 41, 42], it is thought that the magni-
tude of the true placebo effect is generally small in clinical
trials, and that placebo response is primarily driven by
non-specific bias. A recent meta-analysis of pharmaco-
logical trials showed that the effect size in the placebo
arm was indeed larger than in the non-interventional
control arm, which suggests that placebo manipula-
tion exerts some additional effect beyond non-specific
changes [6].
The persistence of placebo response has been explained
in terms of “the learning theory”; i.e. after the withdrawal
of a cue the response does not stop immediately but grad-
ually declines [43]. However, in the analysed trials there
was no significant reduction of the placebo response.
Some of the improvement in the placebo arm might
be related to the effect of concomitant treatment. It is
often assumed that the placebo intervention is truly
inactive and that it does not affect the response in the
placebo group by means other than psychological [44].
However, most of the trials in this review used con-
comitant treatments liable to induce physiological or
pharmacological effects, i.e. standard treatments such
as anti-parkinsonian drugs, rescue medications such
as analgesics or lifestyle modifications, for example
diet or exercise. Therefore, although this study aimed
to include only purely surgical trials, the response in
the placebo arm might encompass other treatments as
opposed to being solely the true placebo effect and
bias. This may explain a larger effect in trials on obes-
ity at the beginning of the follow-up period with diet
and exercise having short-term effects but not long-
term effects.
Part of the response in the placebo arm may be associ-
ated with non-specific factors, such as regression to the
mean and the natural history of the disease. For ex-
ample, a meta-analysis of pain trials reported that higher
pain scores at baseline correlated with a larger placebo
response [7]. It is likely that the sustained positive
change in the placebo arm of trials with subjective out-
comes, especially pain, is to some degree an effect of
“being in the trial”, i.e. receiving additional attention and
support from the clinical staff; the latter being reported
as the most powerful of the non-specific effects [11].
However, it is also likely that some of the observed
change may be the result of patients reporting improve-
ment out of politeness [45] or because their ratings
change with improved well-being or reduced stress [46].
There have been two recent reviews of placebo effect in
surgical trials with a placebo arm. Both studies concen-
trated primarily on the differences in response between
the surgical and placebo arm, and neither of them in-
cluded a comprehensive analysis of temporal changes in
the magnitude of placebo response. Moreover, they
differed slightly in definition of surgery and in their eligi-
bility criteria. In one, the authors did not exclude trials
investigating an invasive delivery of pharmacologically ac-
tive substances, for example the intra-articular injection of
steroids [9]. In the present study, such trials were not
included and analyses were restricted to purely surgi-
cal studies, because of possible differences in placebo
response (including information provided to the pa-
tients and patients’ expectations when a drug treat-
ment was involved) [47]. Another recent review [10]
included procedures which were excluded from this
study, as they did not fulfil our definition of surgery.
Trials with binary outcomes were also excluded, as this
analysis was concerned only with changes in the pla-
cebo arm, unlike the study by Holtedahl et al. [9]
which investigated differences between the surgical
and the placebo arm. Cross-over trials and trials with
only graphical representations of the outcome data
were included. Therefore, only 11 out of 21 studies
analysed by Holtedahl et al. [9] and 24 out of 39 trials
by Jonas et al. [10] were included in this analysis.
Heterogeneity in this study was higher than in another
meta-analysis of surgical RCTs (I2 = 76%) [10] but lower
than in the meta-analysis of individual patient data from
studies on pain in osteoarthritis (I2 = 99%) [7]. The high
heterogeneity could have been caused by the lack of restric-
tions on the types of studies eligible for inclusion. However,
Fig. 12 Funnel plot to determine the presence of publication bias.
Plot of standard error (SE) of SMD versus SMD
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there is evidence that the condition [7] and treatment pro-
cedure may have a weak effect on placebo response [9].
The effect size in the placebo arm was large for sub-
jective outcomes, which is in line with the findings of
other reviews [4, 6, 9]. The effect on pain was larger
than in a meta-analysis of various therapies on musculo-
skeletal pain [6], but this may be related to the invasive-
ness of surgery relative to other treatments [6, 48].
In this analysis, there was no statistically significant
effect for assessed outcomes. It is likely that assessed
outcomes are less influenced by a placebo effect or bias
than subjective ones, but the finding of no statistically
significant effect was unexpected, especially as a signifi-
cant effect for assessed outcomes has been reported else-
where [41]. The number of included trials was small and
the heterogeneity was large; therefore, there may not
have been enough statistical precision to detect a genu-
ine effect.
For trials with objective outcomes, there was no
statistical evidence of significant effect in the placebo
arm. This is in line with the findings of an earlier re-
view, which reported that placebos had no significant
effect on objective outcomes [4]. The lack of placebo
response found by this study suggests that the bias or
non-specific changes may also be small for objective
outcomes.
This is the first study to investigate the temporal
changes of placebo response in surgical RCTs. There
have been attempts to analyse changes of placebo anal-
gesia with time, but the observation period was in the
range of minutes [46, 49], hours [43] or weeks [5].
Within these studies, three investigated single adminis-
tration of a non-invasive placebo, i.e. a capsule or a jelly
[43, 46, 49], and one investigated repeated application of
an invasive placebo, i.e. sham acupuncture [5]. All placebo
procedures resulted in significant pain relief throughout
the observation period. However, only one study per-
formed a formal analysis to investigate the effect of time,
establishing it not to be significant [46].
This is the first study to use meta-regression to inves-
tigate factors affecting placebo response in surgical trials.
The duration of follow-up had no effect in either uni-
variable or multivariable analyses. The strongest pre-
dictor of placebo response was the outcome being
subjective rather than objective, which is in line with
other meta-analyses of true placebo effect [17]. Con-
comitant treatment appeared not to explain the hetero-
geneity present within this study. Randomization ratio
had no effect on the placebo response in our analysis.
Results from other trials provide conflicting evidence,
with some showing that randomization ratio in favour of
active treatment results in a smaller placebo response
[7], whilst others show the opposite [50]. Our analysis
showed that trials located in North America had a
smaller placebo response than those located elsewhere.
A meta-analysis of placebo response in acute migraine
also reported geographic differences, with more pain-
free patients in studies performed in Europe [8]. This
has been interpreted as being related to differences in
patients’ expectations between countries [51].
Implications
Placebo response appears to not change with time and
persists for as long as patients remain blinded and partici-
pating in the trial. Therefore, it may not be possible to
minimize or maximize the magnitude of placebo response
by changing the timings of follow-up time points [47, 52].
This study showed that the placebo response in surgi-
cal trials with subjective outcomes is substantial. There-
fore, patient-oriented outcomes such as pain, function or
quality of life may not be reliable, and trials using such
outcomes may not be able to estimate the true treatment
effect [53]. Where the response in both arms is large
and the difference between arms is small (which is the
situation in some surgical RCTs [1, 10]), even a small
degree of bias may diminish the perceived efficacy of the
treatment [10, 54] and may require a larger sample size
to demonstrate the superiority of an intervention to pla-
cebo [55]. Where possible, objective outcomes should be
used to assess the efficacy of surgical trials. Where this
is not possible, or where subjective outcomes are of pri-
mary interest, placebo control could be necessary to
control for bias from non-specific and placebo effects.
The use of non-interventional groups may also prove
useful where assessors seek to disentangle non-specific
and placebo effects from placebo response.
Placebo response forms part of the response in the
active arm. Therefore, a larger effect in the active arm may
be paralleled by a larger response in the placebo arm [56].
In clinical practice, the placebo effect may be stronger
than in an RCT because the uncertainty about treatment
allocation inherent to a trial might reduce the placebo ef-
fect [57, 58]. Earlier analyses reported that the placebo re-
sponse explains 80% of the variance in the surgical arm
[9] and 65% of the effect in the surgical arm (78% for pain
and 71% for obesity) [10]. However, most of the analysed
trials used concomitant treatment which might have inter-
fered with the true placebo effect. Therefore, in these
instances, the “additive model” may not be valid [47]. This
model assumes that the placebo response is non-specific,
and therefore, the same in the active and in the placebo
arm. The implication is that, although we know that im-
provement in the surgical arm may not just be an effect of
the critical surgical maneuver, we do not know the extent
to which placebo effect and bias contribute. Furthermore,
we do not have a sufficient number of placebo-controlled
surgical RCTs to investigate this.
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Conclusions
To the best of our knowledge, this is the first meta-
analysis to investigate temporal changes in effect in the
placebo groups of surgical RCTs. This paper found evi-
dence that the magnitude of placebo response is not af-
fected by the duration of the follow-up and that this
effect persisted for the duration of blinded assessment.
The most important factor impacting the size of the ef-
fect in the placebo arm is the subjectivity of the outcome
measure. Trials investigating subjective outcomes tended
to have large effects in the placebo arm, whilst trials in-
vestigating assessed or objective outcomes tended to
have no clear effect in the placebo arm.
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